BLUE
Income statement / Annual
Last year (2023), bluebird bio, Inc.'s total revenue was $29.50 M,
an increase of 720.04% from the previous year.
In 2023, bluebird bio, Inc.'s net income was -$211.91 M.
See bluebird bio, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$29.50 M |
$3.60 M |
$3.66 M |
$250.73 M |
$44.67 M |
$54.58 M |
$35.43 M |
$6.16 M |
$14.08 M |
$25.42 M |
| Cost of Revenue |
$33.53 M
|
$10.08 M
|
$38.86 M
|
$5.40 M
|
$2.98 M
|
$885,000.00
|
$1.53 M
|
$204.78 M
|
$123.74 M
|
$62.57 M
|
| Gross Profit |
-$4.03 M
|
-$6.48 M
|
-$35.20 M
|
$245.34 M
|
$41.70 M
|
$53.69 M
|
$33.90 M
|
-$198.62 M
|
-$109.66 M
|
-$37.15 M
|
| Gross Profit Ratio |
-0.14
|
-1.8
|
-9.61
|
0.98
|
0.93
|
0.98
|
0.96
|
-32.27
|
-7.79
|
-1.46
|
| Research and Development Expenses |
$167.65 M
|
$240.76 M
|
$319.95 M
|
$587.96 M
|
$582.41 M
|
$448.59 M
|
$273.04 M
|
$204.78 M
|
$134.04 M
|
$62.57 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$174.13 M
|
$93.55 M
|
$65.12 M
|
$46.21 M
|
$23.23 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$165.51 M
|
$136.91 M
|
$209.97 M
|
$286.90 M
|
$271.36 M
|
$174.13 M
|
$93.55 M
|
$65.12 M
|
$46.21 M
|
$23.23 M
|
| Other Expenses |
-$92.93 M
|
-$102.00 M
|
$27.65 M
|
-$6.50 M
|
-$10.09 M
|
$1.96 M
|
-$1.27 M
|
$3.71 M
|
$2.31 M
|
$120,000.00
|
| Operating Expenses |
$240.23 M
|
$275.67 M
|
$529.92 M
|
$874.85 M
|
$853.78 M
|
$622.72 M
|
$366.59 M
|
$269.89 M
|
$180.25 M
|
$85.80 M
|
| Cost And Expenses |
$273.76 M
|
$285.75 M
|
$568.77 M
|
$880.25 M
|
$856.75 M
|
$623.60 M
|
$368.12 M
|
$269.89 M
|
$180.25 M
|
$85.80 M
|
| Interest Income |
$9.87 M
|
$1.03 M
|
$879,000.00
|
$11.54 M
|
$34.76 M
|
$0.00
|
$0.00
|
$0.00
|
$1.59 M
|
$152,000.00
|
| Interest Expense |
$16.35 M
|
$6.32 M
|
$0.00
|
$0.00
|
$34.76 M
|
$14.62 M
|
$0.00
|
$0.00
|
$1.59 M
|
$152,000.00
|
| Depreciation & Amortization |
$28.53 M
|
$5.00 M
|
$5.45 M
|
$5.63 M
|
$17.43 M
|
$17.16 M
|
$13.54 M
|
$9.65 M
|
$7.42 M
|
$4.23 M
|
| EBITDA |
-$167.16 M |
-$215.56 M |
-$556.93 M |
-$553.63 M |
-$772.72 M |
-$551.87 M |
-$319.15 M |
-$254.47 M |
-$159.30 M |
-$56.15 M |
| EBITDA Ratio |
-5.67
|
-77.07
|
-147.27
|
-2.54
|
-18.12
|
-10.37
|
-9.41
|
-42.18
|
-11.6
|
-2.37
|
| Operating Income Ratio |
-8.28
|
-79.81
|
-161.36
|
-2.51
|
-18.18
|
-10.48
|
-9.38
|
-43.51
|
-12.01
|
-2.38
|
| Total Other Income/Expenses Net |
$32.22 M
|
$19.96 M
|
$28.53 M
|
-$1.11 M
|
$24.67 M
|
$16.59 M
|
-$3.27 M
|
$3.71 M
|
$2.31 M
|
$120,000.00
|
| Income Before Tax |
-$212.04 M
|
-$266.46 M
|
-$562.38 M
|
-$618.01 M
|
-$790.15 M
|
-$555.44 M
|
-$335.43 M
|
-$264.12 M
|
-$166.72 M
|
-$60.51 M
|
| Income Before Tax Ratio |
-7.19
|
-74.08
|
-153.57
|
-2.46
|
-17.69
|
-10.18
|
-9.47
|
-42.91
|
-11.84
|
-2.38
|
| Income Tax Expense |
-$126,000.00
|
$117,000.00
|
$258,000.00
|
$686,000.00
|
-$545,000.00
|
$187,000.00
|
$210,000.00
|
-$612,000.00
|
$60,000.00
|
-$11.80 M
|
| Net Income |
-$211.91 M
|
-$266.58 M
|
-$562.64 M
|
-$618.70 M
|
-$789.61 M
|
-$555.63 M
|
-$335.64 M
|
-$263.51 M
|
-$166.78 M
|
-$48.71 M
|
| Net Income Ratio |
-7.18
|
-74.11
|
-153.64
|
-2.47
|
-17.67
|
-10.18
|
-9.47
|
-42.81
|
-11.85
|
-1.92
|
| EPS |
-1.93 |
-3.39 |
-8.16 |
-9.95 |
-14.31 |
-10.68 |
-7.71 |
-7.07 |
-4.81 |
-1.83 |
| EPS Diluted |
-1.93 |
-3.39 |
-8.16 |
-9.95 |
-14.31 |
-10.68 |
-7.71 |
-7.07 |
-4.81 |
-1.83 |
| Weighted Average Shares Out |
$109.83 M
|
$78.59 M
|
$68.91 M
|
$62.18 M
|
$55.19 M
|
$52.03 M
|
$43.54 M
|
$37.28 M
|
$34.67 M
|
$26.55 M
|
| Weighted Average Shares Out Diluted |
$109.83 M
|
$78.59 M
|
$68.91 M
|
$62.18 M
|
$55.19 M
|
$52.03 M
|
$43.54 M
|
$37.28 M
|
$34.67 M
|
$26.55 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
